STORM Therapeutics Raises $56M Series C to Advance RNA-Modification Cancer Therapy

Why It Matters

The funding accelerates development of a novel RNA‑modifying enzyme inhibitor, potentially delivering the first targeted therapy for sarcomas that lack effective treatments. Success could validate epitranscriptomics as a new drug class in cancer care.

Key Takeaways

• STORM secured €47.5M ($56M) Series C funding.
• Lead candidate STC-15 targets METTL3 enzyme in sarcoma.
• Phase 2 trial dosed first patient, aims for accelerated approval.
• Investors include Pfizer Ventures, M Ventures, Taiho Ventures.
• RNA modification therapy opens new epitranscriptomic oncology frontier.

Pulse Analysis

RNA modification, once a niche research area, is emerging as a viable therapeutic avenue. The enzyme METTL3 adds methyl groups to messenger RNA, influencing cell differentiation and stem‑cell behavior. In cancer, especially sarcomas, aberrant METTL3 activity sustains malignant stem‑cell populations, making it an attractive target. Industry analysts note that epitranscriptomic drugs could complement existing modalities such as immunotherapy and kinase inhibitors, expanding the oncology pipeline beyond DNA‑centric approaches.

STORM Therapeutics’ recent €47.5 million Series C round reflects heightened investor appetite for first‑in‑class epitranscriptomic candidates. Backed by strategic partners like Pfizer Ventures and Taiho Ventures, the capital will propel STC‑15 into Phase 2, where the company aims to demonstrate sufficient efficacy for an accelerated approval route. The trial’s design—single‑agent dosing in selected sarcoma subtypes—mirrors the company’s focus on unmet‑need indications where conventional targeted therapies have limited impact. Early Phase 1 data showing durable tumor regression adds credibility and may attract additional partnership or licensing opportunities.

If STC‑15 meets its clinical milestones, it could reshape sarcoma treatment, a field that accounts for roughly 1 % of adult cancers but suffers from scarce targeted options. An approved METTL3 inhibitor would not only provide a new line of therapy for patients but also validate RNA‑modifying enzymes as druggable targets across oncology. This breakthrough could spur further investment in epitranscriptomic research, prompting larger biotech firms to explore similar mechanisms and potentially accelerating the overall pace of innovation in cancer therapeutics.

Deal Summary

Cambridge-based biotech STORM Therapeutics announced a €47.5 million ($56 million) Series C round from existing investors including M Ventures, Pfizer Ventures, Taiho Ventures, IP Group, UTokyo Innovation Platform and Fast Track Initiative. The funding will support the Phase 2 trial of its METTL3 inhibitor STC-15 for sarcoma. The round was announced on April 16 2026.